Biotech companies operate in a legal minefield. You’ve got researchers walking out the door with proprietary knowledge, regulatory agencies that reward whistleblowers with cash bounties, and funding cycles that force rapid headcount swings. Each of these creates employment litigation exposure that can derail a promising company faster than a failed Phase II trial.
The standard HR playbook doesn’t work here. Your employment decisions carry IP implications. Your terminations trigger regulatory scrutiny. Your contractor relationships blur lines that plaintiff attorneys love to exploit.
This is where many biotech leaders consider a PEO partnership—not for generic payroll processing, but as a structured approach to litigation risk management. When implemented correctly, a PEO can serve as a meaningful buffer between your company and employment claims. When implemented poorly, it creates new vulnerabilities while leaving your most dangerous exposures untouched.
This article walks through a practical framework for evaluating whether a PEO actually reduces your litigation risk, what protections matter specifically for biotech operations, and where the gaps exist that most companies miss until they’re sitting across from plaintiff counsel.
The Unique Litigation Landscape Biotech Companies Navigate
Biotech employment litigation doesn’t look like retail or manufacturing disputes. The stakes are fundamentally different when an employee departure can trigger both wrongful termination claims and trade secret litigation simultaneously.
Consider what happens when you terminate a senior researcher. In most industries, you face potential discrimination or retaliation claims. In biotech, you face those same claims plus immediate concerns about proprietary data walking out the door. The researcher’s next employer might be a competitor. The terminated employee might have access to unpublished trial data worth millions. Suddenly, your termination decision becomes the subject of both employment litigation and IP disputes.
This intersection creates exposure that general employers never face. Plaintiff attorneys in biotech cases routinely argue that terminations were pretextual—designed to silence employees who questioned data integrity or regulatory compliance. These claims trigger whistleblower protections under FDA regulations, SEC rules, and OSHA statutes that provide both financial incentives and retaliation shields for employees who raise concerns.
The regulatory overlay changes everything. A standard wrongful termination claim might settle for $50,000 to $150,000. Add whistleblower allegations involving FDA or SEC violations, and you’re looking at potential damages that include back pay, front pay, emotional distress, punitive damages, and attorney fees that can easily reach seven figures. Understanding wrongful termination risk mitigation becomes essential in this environment.
Rapid scaling compounds these risks. When you’re hiring 20 researchers in three months to meet a trial deadline, documentation suffers. When funding dries up and you need to cut 30% of headcount in a single quarter, termination protocols get rushed. These compression points create exactly the kind of documentation gaps and process inconsistencies that employment litigation thrives on.
Contractor relationships add another layer. Biotech companies routinely engage research personnel as independent contractors to maintain flexibility and control costs. But the line between contractor and employee gets scrutinized intensely when someone files a misclassification claim. If those “contractors” were actually employees under state and federal tests, you’re facing back taxes, penalties, and potential class action exposure.
The point isn’t that biotech is uniquely litigious—it’s that the industry operates at the intersection of multiple high-risk factors that most PEO providers don’t fully understand or adequately address in their standard service packages.
What Co-Employment Actually Protects (And What It Doesn’t)
The term “co-employment” sounds reassuring until you understand what it actually means in litigation. When you engage a PEO, you’re creating a shared employment relationship where both entities have legal obligations and potential liability. The distribution of that liability matters enormously, and it’s rarely as protective as biotech companies assume.
Here’s the fundamental structure: the PEO becomes the employer of record for payroll tax purposes and assumes responsibility for certain employment administration functions. This means the PEO handles payroll processing, tax withholding, benefits administration, and workers’ compensation coverage. In theory, this also means the PEO shares liability for employment practices within their scope of responsibility.
But scope limitations are where most biotech companies get surprised. The PEO’s liability typically extends to administrative employment practices—payroll errors, benefits administration failures, workers’ comp claims. What remains squarely with your company are the decisions that create most biotech litigation exposure: who to hire, who to terminate, how to manage performance, what IP protections to enforce, and how to respond to regulatory concerns raised by employees.
Think about a wrongful termination claim involving a researcher who alleges she was fired for questioning data integrity in a regulatory submission. The PEO didn’t make the termination decision—you did. The PEO didn’t manage the regulatory compliance concerns—you did. The co-employment relationship provides minimal protection because the core liability-generating decisions stayed with your company.
This is where Employment Practices Liability Insurance through PEOs becomes critical to understand. Most PEOs include EPLI coverage as part of their service package, and this coverage can provide meaningful protection against employment claims. But the coverage limits, exclusions, and claim handling procedures vary dramatically across providers.
Standard EPLI policies through PEOs typically cover discrimination, harassment, retaliation, and wrongful termination claims. Coverage limits often range from $1 million to $5 million per occurrence. That sounds substantial until you consider that a single whistleblower claim involving regulatory violations can easily exceed those limits when you factor in punitive damages and attorney fees.
More importantly, EPLI policies routinely exclude or limit coverage for certain claim types that matter in biotech. Many policies exclude claims related to intellectual property disputes, even when those disputes arise from employment relationships. Some exclude or sublimit coverage for regulatory whistleblower claims. Others exclude claims involving executive-level employees or equity compensation disputes.
The real value of PEO partnership for litigation risk isn’t primarily about liability transfer—it’s about process standardization and documentation. PEOs implement structured systems for hiring, onboarding, performance management, and termination that create defensible paper trails. When you’re facing a discrimination claim, having consistent documentation of performance issues, progressive discipline, and legitimate business reasons for termination decisions makes the difference between early settlement and protracted litigation.
PEO systems force documentation discipline that most early-stage biotech companies lack. Every performance conversation gets logged. Every policy acknowledgment gets tracked. Every termination follows a checklist. This standardization doesn’t eliminate claims, but it dramatically improves your defensive position when claims arise.
Building a Risk Mitigation Framework That Actually Fits Biotech
Generic PEO evaluation criteria don’t work for biotech litigation risk. You need a framework that maps your specific exposure points to PEO capabilities that actually address those risks. This requires honest assessment before you ever talk to a PEO provider.
Start by mapping your current litigation exposure points with specificity. Identify which roles have access to proprietary data, unpublished research results, or regulatory submission materials. These are your highest-risk termination scenarios because they carry both employment litigation and IP dispute potential. Document how many employees work across multiple state locations, because multi-state employment creates compliance complexity that increases claim risk. Assess your contractor relationships—how many research personnel are classified as independent contractors, and would those classifications survive scrutiny under applicable tests?
This exposure mapping should produce a clear picture of where your litigation risk concentrates. Maybe you’ve got 15 researchers with access to Phase III trial data working across California, Massachusetts, and New Jersey. Maybe you’ve got 8 contractors performing research functions that look suspiciously like employee work. Maybe you’ve got a pattern of rapid hiring followed by funding-driven layoffs that creates discrimination claim exposure.
Once you understand your exposure profile, you can evaluate PEO capabilities against those specific risks. This is where most biotech companies make their first mistake—they evaluate PEOs based on price per employee per month rather than risk mitigation value.
For EPLI coverage, you need to look beyond the headline limits. Request the actual policy language and review exclusions carefully. Specifically ask: Does the policy cover regulatory whistleblower claims under FDA, SEC, and OSHA statutes? What are the sublimits for punitive damages? Are claims involving IP disputes explicitly excluded? What’s the retention (deductible) per claim? How does the policy handle multi-state employment claims?
Biotech client experience matters more than general PEO experience. A PEO that serves 500 retail and hospitality clients has limited relevant experience for your risk profile. Ask for references from biotech companies at similar stages. Ask how the PEO handles terminations involving employees with access to proprietary research. Ask about their experience with FDA whistleblower claims or SEC retaliation allegations. Companies in pharmaceutical litigation risk mitigation face similar challenges worth understanding.
Multi-state compliance support becomes critical if you’ve got distributed lab operations. Different states have dramatically different employment laws around final pay, non-compete agreements, meal and rest breaks, and termination procedures. Your PEO should demonstrate specific expertise in the states where your employees work, not just generic multi-state capability.
Contract provisions require careful attention to three specific areas. First, indemnification clauses should clearly define which party bears liability for different claim types. Push for language that makes the PEO responsible for claims arising from their administrative failures while accepting that you’ll retain liability for business decisions like hiring and termination. Second, termination assistance provisions should specify exactly what support the PEO provides when you need to terminate high-risk employees—documentation review, legal consultation, process guidance. Third, audit rights should give you the ability to review the PEO’s compliance procedures and EPLI claim handling to ensure they’re actually managing risk effectively.
The framework should also address ongoing relationship management. PEO partnerships aren’t set-and-forget arrangements. You need quarterly reviews of claim trends, annual policy reviews to ensure coverage keeps pace with company growth, and regular compliance updates as regulations change. Build these checkpoints into your contract and your internal processes.
Implementation Failures That Increase Litigation Risk
The transition to PEO partnership creates temporary vulnerabilities that many biotech companies underestimate. You’re moving from one employment structure to another, and the gaps during that transition can generate exactly the kind of claim opportunities you’re trying to avoid.
Carve-out decisions frequently backfire. Many biotech companies decide to keep certain roles outside the PEO relationship—executives, founders, key researchers with equity stakes. The logic seems sound: these are special relationships that don’t fit the PEO model. But carve-outs create two immediate problems.
First, you’ve now got two different employment systems running in parallel. Different policies, different documentation standards, different termination procedures. When you terminate someone in the PEO relationship, they can point to the different treatment afforded to carved-out employees as evidence of discrimination or disparate treatment. Second, you’ve kept your highest-risk employees outside the EPLI coverage and documentation systems that provide the most protection.
The better approach in most cases is to include all employees in the PEO relationship while negotiating specific provisions for executive-level roles. You get consistent systems and documentation while maintaining flexibility for equity compensation and other executive-specific arrangements.
Transition period gaps create acute exposure. During the 30 to 90 days it takes to fully onboard with a PEO, you’re operating in a hybrid state. Some employees have transitioned, others haven’t. Some policies are in effect, others aren’t. This inconsistency creates documentation gaps and process variations that plaintiff attorneys exploit.
The specific risk is that terminations or other adverse employment actions during transition periods lack the documentation and process consistency that make them defensible. If you terminate someone two weeks into your PEO transition, you likely haven’t implemented the full documentation systems yet. The claim that follows will highlight those gaps as evidence of pretextual or discriminatory decision-making. Having a solid employment litigation prevention guide helps navigate these critical periods.
Plan for a complete transition freeze on high-risk employment actions. Unless you have urgent business reasons, avoid terminations, significant compensation changes, or role modifications during the transition period. If you must take action, document extensively and ensure you’re following the new PEO processes even if they’re not fully implemented yet.
Ongoing compliance drift is the most common long-term failure. You implement the PEO partnership with great documentation systems and clear processes. Twelve months later, managers are cutting corners, documentation is slipping, and the discipline that made the system valuable has eroded.
This drift happens because the PEO relationship doesn’t eliminate the need for internal compliance management—it just changes the tools and processes. You still need someone internally ensuring that managers follow documentation requirements, that termination procedures are followed consistently, and that the PEO’s systems are actually being used properly.
Build internal accountability for PEO compliance. Assign someone to audit documentation quarterly. Review termination files to ensure they meet standards. Track whether managers are using the PEO’s performance management systems or reverting to informal processes. The framework requires active management, not passive reliance on the PEO to handle everything.
Recognizing When PEO Partnership Won’t Solve Your Problem
PEOs provide meaningful litigation risk mitigation for many biotech companies, but they’re not universal solutions. Certain scenarios require different approaches, and trying to force a PEO solution where it doesn’t fit actually increases exposure.
Executive and founder disputes fall outside the effective scope of PEO protection. When you’re dealing with a co-founder termination, an executive claiming breach of employment agreement, or equity compensation disputes, the PEO relationship provides minimal value. These disputes involve company-specific agreements, equity structures, and business relationships that the PEO never touched.
You need direct employment counsel for these situations. The PEO’s EPLI coverage likely excludes executive-level claims or has sublimits that don’t provide adequate protection. The documentation systems that work for general employees don’t address the specific issues in executive disputes—board approvals, equity vesting, change of control provisions, non-compete enforcement. Understanding state employment law risk becomes critical when navigating these complex scenarios.
Company size and structure create natural limitations. If you’ve grown to 200+ employees with dedicated in-house HR and legal resources, the value proposition of PEO partnership shifts. You’re paying for administrative services you could handle internally, and the EPLI coverage limits may not scale appropriately to your exposure level.
At a certain size, you’re better served by building internal compliance capabilities and purchasing standalone EPLI coverage with higher limits and fewer exclusions. The breakpoint varies by company, but it’s typically somewhere between 150 and 250 employees where the cost-benefit analysis shifts.
Your specific exposure profile might not match available PEO coverage. If your primary litigation risk involves regulatory whistleblower claims and most PEO EPLI policies exclude or sublimit those claims, you’re not actually addressing your core exposure. If you operate in highly regulated international markets where PEOs lack expertise, the partnership won’t provide the compliance support you need. Conducting a thorough regulatory enforcement risk assessment helps identify these gaps.
In these scenarios, consider alternative approaches. Standalone EPLI policies from specialty carriers often provide broader coverage for biotech-specific risks than bundled PEO policies. You can negotiate higher limits, fewer exclusions, and coverage for claim types that matter in your industry. The premium will be higher, but you’re getting protection that actually addresses your exposure.
In-house compliance buildout makes sense when you have the resources and scale to justify dedicated expertise. Hiring an experienced employment counsel or HR compliance specialist gives you biotech-specific knowledge that most PEOs can’t match. You lose the co-employment liability sharing, but you gain direct control over risk management strategies.
Hybrid models can work for companies in transition. You might use a PEO for general employee population while maintaining direct employment for executives and key researchers. You might purchase standalone EPLI to supplement PEO coverage gaps. You might engage employment counsel for high-risk terminations while relying on the PEO for routine administration.
The key is matching your risk mitigation strategy to your actual exposure profile rather than assuming a PEO partnership automatically solves your litigation problems.
Making the Framework Work in Practice
The framework comes down to four ongoing practices: assess your current exposure honestly, evaluate PEO capabilities against your specific risks, negotiate protections that address biotech litigation realities, and maintain active oversight of the relationship.
Start with exposure assessment. Map where your litigation risk concentrates right now—which roles, which locations, which employment relationships create the highest claim probability. This assessment should update as your company evolves. The risk profile of a 30-person Series A company looks nothing like a 150-person Series C company with multi-state operations.
Evaluate PEO capabilities with specificity. Don’t accept generic claims about employment practices liability coverage or compliance support. Request actual policy language. Ask for biotech client references. Test their knowledge of FDA whistleblower protections and multi-state research operations. The evaluation should produce clear evidence that this PEO actually understands and can address your specific risks.
Negotiate contract provisions that matter. Standard PEO agreements are written to protect the PEO, not to maximize your risk mitigation. Push for clear indemnification boundaries, specific termination assistance commitments, and audit rights that give you visibility into how they’re actually managing claims. These provisions become critical when you’re facing litigation and need to understand what protection you actually have.
Maintain active oversight throughout the relationship. Quarterly compliance reviews, annual policy updates, ongoing training for managers on documentation requirements. The PEO provides tools and systems, but you’re responsible for ensuring they’re used effectively.
The goal isn’t eliminating litigation risk—that’s impossible in biotech. The goal is structuring your employment relationships to minimize exposure where possible and maximize defensibility when claims arise. A well-implemented PEO partnership serves that goal. A poorly implemented one creates new vulnerabilities while leaving your most dangerous exposures untouched.
Before you sign that PEO renewal, make sure you’re not leaving money on the table.
Many businesses unknowingly overpay because of bundled fees, hidden administrative markups, and contracts designed to limit flexibility. We give you a clear, side-by-side breakdown of pricing, services, and contract terms—so you can see exactly what you’re paying for and choose the option that truly fits your business.
